CKS1B was previously reported to promote drug resistance in myeloma cells through activation of the JAK/STAT3 signaling pathway, which revealed a link between CKS1B and JAK/STAT3 pathway (Shi et al. 2010). Here, CKS1B is linked to plasma cell myeloma.